143 related articles for article (PubMed ID: 28951087)
1. Investigating the candidacy of a capsular polysaccharide-based glycoconjugate as a vaccine to combat Haemophilus influenzae type a disease: A solution for an unmet public health need.
Cox AD; Williams D; Cairns C; St Michael F; Fleming P; Vinogradov E; Arbour M; Masson L; Zou W
Vaccine; 2017 Oct; 35(45):6129-6136. PubMed ID: 28951087
[TBL] [Abstract][Full Text] [Related]
2. Prevention of Haemophilus influenzae type b colonization by vaccination: correlation with serum anti-capsular IgG concentration.
Fernandez J; Levine OS; Sanchez J; Balter S; LaClaire L; Feris J; Romero-Steiner S
J Infect Dis; 2000 Nov; 182(5):1553-6. PubMed ID: 11023481
[TBL] [Abstract][Full Text] [Related]
3. Natural immunity against Haemophilus influenzae type a and B-cell subpopulations in adult patients with severe chronic kidney disease.
Gaultier GN; McCready W; Ulanova M
Vaccine; 2019 Jun; 37(28):3677-3684. PubMed ID: 31122854
[TBL] [Abstract][Full Text] [Related]
4. [Polysaccharide vaccines against Haemophilus influenzae type B].
Wysokińska T; Janaszek W
Przegl Epidemiol; 1994; 48(1-2):39-44. PubMed ID: 8073141
[TBL] [Abstract][Full Text] [Related]
5. Haemophilus influenzae: capsule vaccine and capsulation genetics.
Kroll JS; Booy R
Mol Med Today; 1996 Apr; 2(4):160-5. PubMed ID: 8796878
[TBL] [Abstract][Full Text] [Related]
6. Characterization of natural bactericidal antibody against Haemophilus influenzae type a in Canadian First Nations: A Canadian Immunization Research Network (CIRN) Clinical Trials Network (CTN) study.
Nix EB; Choi J; Anthes C; Gaultier GN; Thorgrimson J; Cox AD; Tsang RSW; McCready WG; Boreham D; Ulanova M
PLoS One; 2018; 13(8):e0201282. PubMed ID: 30110339
[TBL] [Abstract][Full Text] [Related]
7. Protection against Streptococcus suis Serotype 2 Infection Using a Capsular Polysaccharide Glycoconjugate Vaccine.
Goyette-Desjardins G; Calzas C; Shiao TC; Neubauer A; Kempker J; Roy R; Gottschalk M; Segura M
Infect Immun; 2016 Jul; 84(7):2059-2075. PubMed ID: 27113360
[TBL] [Abstract][Full Text] [Related]
8. Haemophilus influenzae serotype b vaccine failure: what is the significance of antibody levels?
Spanjaard L; Rijkers GT
Clin Infect Dis; 2009 Aug; 49(3):381-2. PubMed ID: 19580417
[No Abstract] [Full Text] [Related]
9. Safety and immunogenicity of Haemophilus influenzae type b oligosaccharide-CRM197 conjugate vaccine in infants aged 15 to 23 months.
Madore DV; Johnson CL; Phipps DC; Myers MG; Eby R; Smith DH
Pediatrics; 1990 Oct; 86(4):527-34. PubMed ID: 2216616
[TBL] [Abstract][Full Text] [Related]
10. Molecular characteristics of Haemophilus influenzae causing invasive disease during the period of vaccination in Switzerland: analysis of strains isolated between 1986 and 1993.
Muhlemann K; Balz M; Aebi S; Schopfer K
J Clin Microbiol; 1996 Mar; 34(3):560-3. PubMed ID: 8904414
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of a new Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) (PedvaxHIB).
Vella PP; Staub JM; Armstrong J; Dolan KT; Rusk CM; Szymanski S; Greer WE; Marburg S; Kniskern PJ; Schofield TL
Pediatrics; 1990 Apr; 85(4 Pt 2):668-75. PubMed ID: 2107517
[TBL] [Abstract][Full Text] [Related]
12. The human B-lymphocyte response to Haemophilus influenzae type b capsular polysaccharide coupled to protein.
Barington T
APMIS Suppl; 1995; 56():1-40. PubMed ID: 8546878
[No Abstract] [Full Text] [Related]
13. No evidence for Haemophilus influenzae serotype replacement in Europe after introduction of the Hib conjugate vaccine.
Ladhani S; Ramsay ME; Chandra M; Slack MP;
Lancet Infect Dis; 2008 May; 8(5):275-6. PubMed ID: 18471770
[No Abstract] [Full Text] [Related]
14. A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b.
Verez-Bencomo V; Fernández-Santana V; Hardy E; Toledo ME; Rodríguez MC; Heynngnezz L; Rodriguez A; Baly A; Herrera L; Izquierdo M; Villar A; Valdés Y; Cosme K; Deler ML; Montane M; Garcia E; Ramos A; Aguilar A; Medina E; Toraño G; Sosa I; Hernandez I; Martínez R; Muzachio A; Carmenates A; Costa L; Cardoso F; Campa C; Diaz M; Roy R
Science; 2004 Jul; 305(5683):522-5. PubMed ID: 15273395
[TBL] [Abstract][Full Text] [Related]
15. Opsonophagocidal activity in sera from infants and children immunized with Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate).
Gray BM
Pediatrics; 1990 Apr; 85(4 Pt 2):694-7. PubMed ID: 2107521
[TBL] [Abstract][Full Text] [Related]
16. Haemophilus influenzae serotype a as a cause of serious invasive infections.
Ulanova M; Tsang RSW
Lancet Infect Dis; 2014 Jan; 14(1):70-82. PubMed ID: 24268829
[TBL] [Abstract][Full Text] [Related]
17. The changing epidemiology of invasive Haemophilus influenzae disease: Emergence and global presence of serotype a strains that may require a new vaccine for control.
Tsang RSW; Ulanova M
Vaccine; 2017 Jul; 35(33):4270-4275. PubMed ID: 28666758
[TBL] [Abstract][Full Text] [Related]
18. [Vaccination against Haemophilus influenzae].
Huber EG
Padiatr Padol; 1991; 26(4):203-4. PubMed ID: 1749631
[No Abstract] [Full Text] [Related]
19. Naturally acquired antibodies against Haemophilus influenzae type a in Aboriginal adults, Canada.
Nix EB; Williams K; Cox AD; St Michael F; Romero-Steiner S; Schmidt DS; McCready WG; Ulanova M
Emerg Infect Dis; 2015 Feb; 21(2):273-9. PubMed ID: 25626129
[TBL] [Abstract][Full Text] [Related]
20. [When should vaccination against Haemophilus influenzae type b take place?].
Stickl HA
Med Monatsschr Pharm; 1991 Jan; 14(1):24. PubMed ID: 2017108
[No Abstract] [Full Text] [Related]
[Next] [New Search]
